# The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.

> **NCT07750249** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **University Hospital, Martin** · enrollment: 120 (estimated)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** SCFA → Placebo (Sequence SP) and Placebo → SCFA (Sequence PS)

## Key facts

- **NCT ID:** NCT07750249
- **Lead sponsor:** University Hospital, Martin
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-03-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750249, "The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*